Plasma SARS-CoV-2 RNA Levels in Critically Ill COVID-19 Patients
NCT ID: NCT05115045
Last Updated: 2023-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
122 participants
OBSERVATIONAL
2021-11-09
2022-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
NCT05162508
PREdiction of DIagnosed Covid-19 infecTion in IUC Patients
NCT04327180
Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients
NCT04516486
Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)
NCT04948242
One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU)
NCT04401111
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
plasmatic SARS-CoV-2 RNA quantification
plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* in ICU hospitalization
* COVID-19 related pneumonia confirmed by PCR
Exclusion Criteria
* patient's refusal to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hopital of Melun
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sebastien Jochmans, MD
Head of Clinical Research Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
SEBASTIEN JOCHMANS
Role: STUDY_DIRECTOR
GHSIF MELUN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Sud Ile de France, Hôpital de Melun-Sénart
Melun, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Veyer D, Kerneis S, Poulet G, Wack M, Robillard N, Taly V, L'Honneur AS, Rozenberg F, Laurent-Puig P, Belec L, Hadjadj J, Terrier B, Pere H. Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical Value. Clin Infect Dis. 2021 Nov 2;73(9):e2890-e2897. doi: 10.1093/cid/ciaa1196.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-MIR-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.